Next Article in Journal
Diagnostics Literacy Advocacy Model for Vulnerable Populations
Previous Article in Journal
Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV
 
 
Systematic Review
Peer-Review Record

The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review

Diagnostics 2022, 12(3), 715; https://doi.org/10.3390/diagnostics12030715
by Okker D. Bijlstra 1,2,*, Maud M. E. Boreel 1, Sietse van Mossel 3, Mark C. Burgmans 4, Ellen H. W. Kapiteijn 5, Daniela E. Oprea-Lager 6, Daphne D. D. Rietbergen 3, Floris H. P. van Velden 3, Alexander L. Vahrmeijer 1, Rutger-Jan Swijnenburg 2, J. Sven D. Mieog 1 and Lioe-Fee de Geus-Oei 3,7
Reviewer 1:
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Diagnostics 2022, 12(3), 715; https://doi.org/10.3390/diagnostics12030715
Submission received: 18 February 2022 / Revised: 4 March 2022 / Accepted: 5 March 2022 / Published: 15 March 2022

Round 1

Reviewer 1 Report

Review is good for clinical practice.

I don't have any issues to changes anything major. Systematic review is helpful for service to patients as better quality of data.

Author Response

Dear reviewer,

Thank you for reviewing this manuscript and your positive comments.

Yours sincerely,

O.D. Bijlstra

Reviewer 2 Report

This is a well-written and well-structured systematic review on the important topic of the role of FDG PET-CT for treatment evaluation for CRLM. All the important studies are included and the main topics are addressed.

I only have a few minor comments.

Introduction, line 69: … after intravenous contrast ceCT – this sentence seems incomplete and needs rewording.

Introduction, line 99/100: SUVmax should be included into the semiquantitative clinical parameters.

Author Response

Dear Reviewer,

Thank you for reviewing this manuscript and for providing us suggestions for improvement.

  1. I have changed the incomplete sentence in line 69 in the Introduction;
  2. SUVmax was already mentioned as semiquantitative parameter in lines 95-96. We chose to mention SUVmax separately since it is the most commonly used parameter.

Yours sincerely,

O.D. Bijlstra 

Reviewer 3 Report

The paper is interesting and subject is well developed.

Some suggestions:

  • I encourage authors to add, if availables, some emblematic figures with captions showing the performance of 18FDG-PET-CT in detecting local tumor progression after thermal ablation (in addition to Fig. 2), in response monitoring after neoadiuvant chemotherapy, during and after palliative chemotherapy and after radioembolization;
  • In Table 2 and in Tabe 5 articles should be presented with the same order of references;
  • Tables 2-3-4-5 are very full: it is advisable to use abbreviations whenever possible (prospective/retrospective, chemotherapy,...).

Author Response

Dear Reviewer,

Thank you for reviewing this manuscript and for providing us comments for improvement.

  1. I have added images from a chemotherapy patient and a radioembolization patient as per your request;
  2. I have reordered the results in tables 2 and 5. They now display the same order as the main text;
  3. We agree the tables are very full, however, in our opinion the readability of the table will decrease when using more abbreviations

Yours sincerely,

O.D. Bijlstra

Back to TopTop